What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.”In the company’s words, NCT04999761 on ClinicalTrials.gov
- Tested for
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer and 1 more
- Main trialPhase 1
- “This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.”In the company’s words, NCT04999761 on ClinicalTrials.gov
Other drugs for Advanced or Metastatic Solid Tumor
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up1
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2027 | AB122 Platform Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026